Mouse Models of Wet AMD in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Wet AMD
Neovascular AMD is a human disease of the macula, involving new vessel growth that most commonly arises from the choroid, either remaining beneath the retinal pigment epithelium or entering the subretinal space, with a third form originating in the retinal circulation.
Where the vessels leak, that leakage is directly imageable, which is why angiography recurs as a readout in this literature.
Wet AMD in Experimental Research
The species here have no macula, so this work models components of neovascular AMD, most directly the neovascular process, without reproducing the macular anatomy of the human disease.
In much of this literature choroidal neovascularization is induced by laser and read out in a non-macular retina.
Mouse Models of Wet AMD
The mouse carries most of this work.
Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.
A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.
Published MICRON Research: Wet AMD in Mice
This page lists 182 papers from the MICRON literature, published 2013 to 2026, that study neovascular (wet) age-related macular degeneration in mice.
Of these publications:
- 180 studies used mice as the primary wet age-related macular degeneration disease model.
- 2 studies used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published wet age-related macular degeneration research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Laser Photocoagulation Models | 122 |
| Fundus Fluorescein Angiography | 120 |
| Intravitreal Injection / Delivery | 113 |
| Optical Coherence Tomography | 89 |
| Topical Ophthalmic Drug Delivery | 47 |
| Electroretinography | 39 |
| AAV-Mediated Ocular Gene Delivery | 17 |
| Ocular Implants / Sustained Release | 1 |
| Optokinetic / Optomotor Response | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
AAV-Mediated Ocular Gene Delivery
An adeno-associated viral vector delivers genetic material to ocular cells, and a single administration can support long-lived transgene expression. That persistence is useful for gene augmentation and sustained therapeutic-protein expression; AAV can also deliver gene-silencing or genome-editing cargo, where long-lived expression of the editing machinery may be unnecessary or undesirable. Capsid and route of delivery jointly determine which cells are reached, so different delivery routes and vector designs give different distributions.
Ocular Implants / Sustained Release
A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.
Optokinetic / Optomotor Response
Measures a reflexive head or eye movement tracking a moving pattern, giving a rapid, training-free behavioral estimate of spatial vision and contrast sensitivity in an animal that cannot report them. It is driven largely by reflex circuitry and reports on the visual pathway as a whole, so a deficit it detects still has to be localized by a structural or electrophysiological method, or separated from cortical processing by an operant task.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| MICRON IV | 124 |
| Image-Guided Laser | 87 |
| MICRON III | 57 |
| Image-Guided OCT | 49 |
| Image-Guided Focal ERG | 6 |
| Insight Software | 4 |
| Ganzfeld ERG System | 3 |
| MICRON (Unspecified) | 3 |
| MICRON 5 | 2 |
| Anterior Segment Imaging System | 1 |
| MICRON II | 1 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| C57BL/6J | 117 | C57/BL6J, C57/Bl6J, C57B/6J, C57BL/6 J, C57BL/J6, C57BL6/J, C57Bl/6 J, C57Bl6/J |
| C57BL/6 | 41 | C57/BL/6, C57BL6, C57Bl/6 |
| C57BL/6JRj | 2 | |
| JR5558 | 2 | |
| 129S6 | 1 | |
| BALB/c | 1 | |
| C57BL/6 (JR5558) | 1 | |
| C57BL/6Jmsslc | 1 | |
| C57BL/6N | 1 | |
| C57Bl6JARC | 1 | |
| Vldlr−/− | 1 | |
| rd10 | 1 |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Rabbit | 10 |
| Rat | 7 |
| Swine / Domestic Pig | 7 |
| Cynomolgus Macaque | 4 |
| Rhesus Macaque | 3 |
| Zebrafish | 2 |
| Macaque (Unspecified) | 1 |
| Minipig | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Choroidal Neovascularization | 169 |
| Age-Related Macular Degeneration (General) | 166 |
| Retinal Neovascularization (General) | 34 |
| Age-Related Macular Degeneration (Dry/Atrophic) | 20 |
| Retinal Pigment Epithelium Dysfunction | 18 |
| Retinopathy of Prematurity | 12 |
| Diabetic Retinopathy | 10 |
| Retinal Degeneration (General) | 10 |
| Retinal Detachment | 6 |
| Retinal Drusen | 4 |
| Diabetes Mellitus, Type 1 | 2 |
| Light-Induced Retinal Degeneration | 2 |
| Retinal Vein Occlusion (RVO) | 2 |
| Corneal Neovascularization | 1 |
| Corneal Wound Healing | 1 |
| Epiretinal Membrane | 1 |
| Glaucoma (General) | 1 |
| Retinitis Pigmentosa (RP) | 1 |
| Retinoblastoma | 1 |
| Stargardt Disease | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| MICRON IV | 124 | Laser Photocoagulation Models (86), Fundus Fluorescein Angiography (84), Intravitreal Injection / Delivery (81) |
| Image-Guided Laser | 87 | Laser Photocoagulation Models (66), Fundus Fluorescein Angiography (60), Intravitreal Injection / Delivery (60) |
| MICRON III | 57 | Laser Photocoagulation Models (37), Fundus Fluorescein Angiography (36), Intravitreal Injection / Delivery (32) |
| Image-Guided OCT | 49 | Optical Coherence Tomography (47), Intravitreal Injection / Delivery (36), Fundus Fluorescein Angiography (35) |
| Image-Guided Focal ERG | 6 | Electroretinography (6), Intravitreal Injection / Delivery (5), Optical Coherence Tomography (5) |
| Insight Software | 4 | Fundus Fluorescein Angiography (4), Intravitreal Injection / Delivery (4), Laser Photocoagulation Models (4) |
| Ganzfeld ERG System | 3 | Electroretinography (3), Fundus Fluorescein Angiography (3), Laser Photocoagulation Models (3) |
| MICRON (Unspecified) | 3 | Intravitreal Injection / Delivery (2), Laser Photocoagulation Models (2), Fundus Fluorescein Angiography (1) |
| MICRON 5 | 2 | Fundus Fluorescein Angiography (2), Intravitreal Injection / Delivery (2), Laser Photocoagulation Models (2) |
| Anterior Segment Imaging System | 1 | Fundus Fluorescein Angiography (1), Intravitreal Injection / Delivery (1), Laser Photocoagulation Models (1) |
| MICRON II | 1 | AAV-Mediated Ocular Gene Delivery (1), Fundus Fluorescein Angiography (1), Optical Coherence Tomography (1) |
The papers
The table lists the 20 most recent papers in the cohort.
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2026 | Mononuclear phagocyte–specific cGAS/STING targeting suppresses experimental choroidal neovascularization | JCI Insight | Disease model | Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2026 | FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling. | Nature Communications | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2026 | Endothelial TGFβ signaling modulates choroidal neovascularization severity via myeloid–endothelial cell interaction | Frontiers in Immunology | Disease model | MICRON IV | DOI · reSEARCH |
| 2026 | Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy | Signal Transduction and Targeted Therapy | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2026 | Engineered RPE Cell Therapy for Controllable Anti-VEGF Delivery in Neovascular AMD | Research Square | Disease model | Image-Guided Laser, Image-Guided OCT, Insight Software, MICRON III | DOI · reSEARCH |
| 2026 | RAGE Inhibition by TTP488 Suppresses Macrophage-Associated Inflammation and Enhances Anti-VEGF Efficacy in Experimental Choroidal Neovascularization | Research Square | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2026 | Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration. | Journal of Controlled Release | Disease model | Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2026 | Development and characterization of a topical ferrochelatase inhibitor nanoemulsion for choroidal neovascularization therapy. | International Journal of Pharmaceutics: X | Disease model | Anterior Segment Imaging System, Image-Guided Laser, Image-Guided OCT, MICRON 5 | DOI · reSEARCH |
| 2026 | Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. | Cell Reports. Medicine | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2026 | RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD. | Investigative Ophthalmology & Visual Science | Disease model | Image-Guided Focal ERG, MICRON III | DOI · reSEARCH |
| 2026 | TNFAIP3 in M2 Macrophage Attenuates Subretinal Fibrosis in Laser-Induced Murine Model. | Investigative Ophthalmology & Visual Science | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2026 | Eye Drop Development of Anti-VEGF Therapeutics by Ocular Penetrating Carrier to the Posterior Region of the Eye. | Translational Vision Science & Technology | Disease model | Image-Guided Laser, Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2026 | Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model. | Molecular Therapy. Advances | Disease model | Image-Guided Focal ERG, Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2026 | Inhibition of Pathological Mitochondrial Fission in Retinal Pigment Epithelium Mitigates Choroidal Neovascularization. | Investigative Ophthalmology & Visual Science | Disease model | MICRON IV | DOI · reSEARCH |
| 2026 | An siRNA targeting S6k1 identifies photoreceptor phospholipid metabolism as a contributor to lipid buildup in age-related macular degeneration | Molecular Therapy Nucleic Acids | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2026 | Ethyl ferulate suppresses choroidal neovascularization by accelerating Keap1 degradation through the inhibition of PSMD14-mediated deubiquitination. | Phytomedicine | Disease model | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2026 | AAV-mediated multiple gene therapy combining VEGFA-targeting miR-agshRNAs and PEDF for the suppression of choroidal neovascularization. | Molecular Therapy. Nucleic Acids | Disease model | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Charakterisierung der PLX5622 vermittelten Depletion von Mikroglia in der Retina | Online Publication Service of Würzburg University | Disease model | MICRON IV | DOI · reSEARCH |
| 2025 | Dysregulated Proline Metabolism Contributes to Subretinal Fibrosis in Neovascular AMD: Therapeutic Potential of Prolyl-4-Hydroxylase Inhibition | bioRxiv | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | circSIRT2/miR-542-3p/VASH1 axis regulates endothelial-to-mesenchymal transition (EndMT) in subretinal fibrosis in age-related macular degeneration models. | Aging Cell | Disease model | Image-Guided OCT, MICRON (Unspecified) | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.